Cover Image
Market Research Report

Europe Drug Discovery Market Forecast 2019-2027

Published by Inkwood Research Product code 609208
Published Content info 92 Pages
Delivery time: 2-3 business days
Price
Back to Top
Europe Drug Discovery Market Forecast 2019-2027
Published: August 12, 2019 Content info: 92 Pages
Description

KEY FINDINGS

The European drug discovery market is projected to rise with a CAGR of 8.22% during the forecast years of 2019-2027. By the end of 2027, the Europe market is expected to reach a worth of $XX million and capture XX% market share in the global drug discovery market. The European healthcare market is equipped with comprehensive and updated technology, which showcase tremendous growth potential for the drug discovery market.

MARKET INSIGHTS

The European drug discovery market is mainly influenced by the contributing countries such as France, Germany, Italy, Spain, and the United Kingdom. The report also analyzed the Rest of Europe regional segment that is formed by a conglomeration of other remaining countries. The healthcare spending of European countries is increasing considerably. Also, as the incidences of chronic diseases are rising in the region, which leads to surging demand for specialty medicines, in turn, fueling drug discovery market growth. In addition, implementation of drug discovery programs across the European countries is boosting the market demand. However, stringent government regulations delaying the processes for product launches could significantly restrain the market growth.

COMPETITIVE INSIGHTS

Novartis, Johnson and Johnson, Merck & Co. Inc., Pfizer Inc., GlaxoSmithKline LLC, and Sanofi, are few of the renowned players operating in the drug discovery market. The market is highly competitive due to the presence of giant multinational companies. However, the new entrants face the entry-level barrier due to the high capital requirement for research & development of new drugs.

Table of Contents
Product Code: 13804

Table of contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. HIGH PREVALENCE RATES OF MAJOR HEALTH DISORDERS
    • 3.2.2. IMPLEMENTATION OF DRUG DISCOVERY PROGRAMS
    • 3.2.3. BIOINFORMATICS IS THE WIDELY USED DRUG DISCOVERY TECHNOLOGY
    • 3.2.4. SMALL MOLECULE DRUG TYPE CONSTITUTES THE HIGHEST MARKET SHARE
    • 3.2.5. CONTRACT RESEARCH ORGANIZATIONS (CROS) ARE THE FASTEST-GROWING END USER

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. AGING POPULATION
    • 4.2.2. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST COMPARED TO GENERIC DRUGS
    • 4.2.3. GROWING HEALTHCARE EXPENDITURE
    • 4.2.4. TECHNOLOGICAL ADVANCEMENT
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. DELAY IN PRODUCT LAUNCHES
    • 4.3.2. POOR ACCESS TO HEALTHCARE SERVICES IN DEVELOPING MARKETS
    • 4.3.3. SHIFT FROM BRANDED TO GENERIC DRUGS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
    • 4.4.2. INCREASING DEMAND FOR SPECIALTY MEDICINES
    • 4.4.3. RISING INVESTMENT BY PHARMACEUTICAL COMPANIES IN IMPROVING BIG-DATA ANALYTICAL CAPABILITIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
    • 4.5.2. STRINGENT GOVERNMENT REGULATIONS

5. MARKET BY TECHNOLOGY

  • 5.1. HIGH THROUGHPUT SCREENING
  • 5.2. BIOCHIPS
  • 5.3. BIOINFORMATICS
  • 5.4. PHARMACOGENOMICS AND PHARMACOGENETICS
  • 5.5. COMBINATORIAL CHEMISTRY
  • 5.6. NANOTECHNOLOGY
  • 5.7. SPECTROSCOPY
  • 5.8. METABOLOMICS
  • 5.9. OTHER TECHNOLOGIES

6. MARKET BY DRUG TYPE

  • 6.1. SMALL MOLECULE DRUG
  • 6.2. BIOLOGIC DRUG

7. MARKET BY SERVICE

  • 7.1. DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
  • 7.2. CHEMICAL SERVICES
  • 7.3. BIOLOGICAL SERVICES
  • 7.4. OTHER PHARMACEUTICAL SERVICES

8. MARKET BY END USER

  • 8.1. RESEARCH INSTITUTES
  • 8.2. PHARMACEUTICAL COMPANIES
  • 8.3. CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 8.4. OTHER END USER

9. KEY ANALYTICS

  • 9.1. PORTER'S FIVE FORCES MODEL
    • 9.1.1. THREATS OF NEW ENTRANTS
    • 9.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 9.1.3. BARGAINING POWER OF BUYERS
    • 9.1.4. BARGAINING POWER OF SUPPLIERS
  • 9.2. COMPETITIVE RIVALRY
  • 9.3. VALUE CHAIN ANALYSIS
  • 9.4. PESTLE ANALYSIS
  • 9.5. REGULATORY FRAMEWORK
  • 9.6. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS

  • 10.1. EUROPE
    • 10.1.1. THE UNITED KINGDOM
    • 10.1.2. FRANCE
    • 10.1.3. GERMANY
    • 10.1.4. SPAIN
    • 10.1.5. ITALY
    • 10.1.6. REST OF EUROPE

11. COMPANY PROFILES

  • 11.1. 3M COMPANY
  • 11.2. ANTARES PHARMA
  • 11.3. ASTRAZENECA PLC
  • 11.4. BAYER AG
  • 11.5. BECTON, DICKINSON & COMPANY (BD)
  • 11.6. BOEHRINGER INGELHEIM
  • 11.7. ELI LILY
  • 11.8. F. HOFFMANN-LA ROCHE LTD
  • 11.9. GLAXOSMITHKLINE LLC
  • 11.10. JOHNSON AND JOHNSON
  • 11.11. MERCK & CO. INC.
  • 11.12. NOVARTIS
  • 11.13. PFIZER, INC.
  • 11.14. SANOFI

LIST OF TABLES

  • TABLE 1 EUROPE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • TABLE 2 EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2019-2027 ($ MILLION)
  • TABLE 3 EUROPE HIGH THROUGHPUT SCREENING MARKET, 2019-2027 ($ MILLION)
  • TABLE 4 EUROPE BIOCHIPS MARKET, 2019-2027 ($ MILLION)
  • TABLE 5 EUROPE BIOINFORMATICS MARKET, 2019-2027 ($ MILLION)
  • TABLE 6 EUROPE PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, 2019-2027 ($ MILLION)
  • TABLE 7 EUROPE COMBINATORIAL CHEMISTRY MARKET, 2019-2027 ($ MILLION)
  • TABLE 8 EUROPE NANOTECHNOLOGY MARKET, 2019-2027 ($ MILLION)
  • TABLE 9 EUROPE SPECTROSCOPY MARKET, 2019-2027 ($ MILLION)
  • TABLE 10 EUROPE METABOLOMICS MARKET, 2019-2027 ($ MILLION)
  • TABLE 11 EUROPE OTHER TECHNOLOGIES MARKET, 2019-2027 ($ MILLION)
  • TABLE 12 EUROPE DRUG DISCOVERY MARKET, BY DRUG TYPE, 2019-2027 ($ MILLION)
  • TABLE 13 EUROPE SMALL MOLECULE DRUG MARKET, 2019-2027 ($ MILLION)
  • TABLE 14 EUROPE BIOLOGIC DRUG MARKET, 2019-2027 ($ MILLION)
  • TABLE 15 EUROPE DRUG DISCOVERY MARKET, BY SERVICE, 2019-2027 ($ MILLION)
  • TABLE 16 EUROPE DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 17 EUROPE CHEMICAL SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 18 EUROPE BIOLOGICAL SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 19 EUROPE OTHER PHARMACEUTICAL SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 20 EUROPE DRUG DISCOVERY MARKET, BY END USER, 2019-2027 ($ MILLION)
  • TABLE 21 EUROPE RESEARCH INSTITUTES MARKET, 2019-2027 ($ MILLION)
  • TABLE 22 EUROPE PHARMACEUTICAL COMPANIES MARKET, 2019-2027 ($ MILLION)
  • TABLE 23 EUROPE CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET, 2019-2027 ($ MILLION)
  • TABLE 24 EUROPE OTHER END USER MARKET, 2019-2027 ($ MILLION)
  • TABLE 25 EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 EUROPE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 2 EUROPE DRUG DISCOVERY MARKET SHARE BY TECHNOLOGY 2018 & 2027 (%)
  • FIGURE 3 EUROPE DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2019-2027 ($ MILLION)
  • FIGURE 4 EUROPE DRUG DISCOVERY MARKET, BY BIOCHIPS, 2019-2027 ($ MILLION)
  • FIGURE 5 EUROPE DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2019-2027 ($ MILLION)
  • FIGURE 6 EUROPE DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2019-2027 ($ MILLION)
  • FIGURE 7 EUROPE DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2019-2027 ($ MILLION)
  • FIGURE 8 EUROPE DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2019-2027 ($ MILLION)
  • FIGURE 9 EUROPE DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2019-2027 ($ MILLION)
  • FIGURE 10 EUROPE DRUG DISCOVERY MARKET, BY METABOLOMICS, 2019-2027 ($ MILLION)
  • FIGURE 11 EUROPE DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2019-2027 ($ MILLION)
  • FIGURE 12 EUROPE DRUG DISCOVERY MARKET SHARE BY DRUG TYPE 2018 & 2027 (%)
  • FIGURE 13 EUROPE DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2019-2027 ($ MILLION)
  • FIGURE 14 EUROPE DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2019-2027 ($ MILLION)
  • FIGURE 15 EUROPE DRUG DISCOVERY MARKET SHARE, BY SERVICE, 2018 & 2027 (%)
  • FIGURE 16 EUROPE DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 17 EUROPE DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 18 EUROPE DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 19 EUROPE DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 20 EUROPE DRUG DISCOVERY MARKET SHARE, BY END USER, 2018 & 2027 (%)
  • FIGURE 21 EUROPE DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2019-2027 ($ MILLION)
  • FIGURE 22 EUROPE DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2019-2027 ($ MILLION)
  • FIGURE 23 EUROPE DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), 2019-2027 ($ MILLION)
  • FIGURE 24 EUROPE DRUG DISCOVERY MARKET, BY OTHER END USER, 2019-2027 ($ MILLION)
  • FIGURE 25 PORTER'S FIVE FORCE MODEL
  • FIGURE 26 EUROPE DRUG DISCOVERY MARKET, REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 27 THE UNITED KINGDOM DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 28 FRANCE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 29 GERMANY DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 30 SPAIN DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 31 ITALY DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 32 REST OF EUROPE DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
Back to Top